Tenil http://www.tenil.net/ Tue, 05 Jul 2022 03:09:39 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://www.tenil.net/wp-content/uploads/2021/05/tenil-icon-150x150.png Tenil http://www.tenil.net/ 32 32 Chronic Obstructive Pulmonary Disease Market Size, Scope and Forecast https://www.tenil.net/chronic-obstructive-pulmonary-disease-market-size-scope-and-forecast/ Tue, 05 Jul 2022 03:09:39 +0000 https://www.tenil.net/chronic-obstructive-pulmonary-disease-market-size-scope-and-forecast/

New Jersey, United States – The Chronic Obstructive Pulmonary Disease Market The research report aims to provide a quick overview of the overall industry performance and important new trends. Important information, as well as conclusions, latest key drivers and constraints, are also described here. A wide range of quantitative and qualitative techniques are used by market analysts, including in-depth interviews, ethnography, customer surveys, and secondary data analysis. It becomes easy for major players to collect important data regarding key organizations along with information such as customer behavior, market size, competition and market needs. By referring to this Chronic Obstructive Pulmonary Disease Market research report, it becomes easy for key players to make evidence-based decisions.

This Chronic Obstructive Pulmonary Disease Market research report adds the potential to impact its readers and users as market growth rate is affected by innovative products, increase in demand for the product, the richness in raw materials, the increase in disposable income and the modification of consumer technologies. It also covers the effect of COVID-19 virus on market growth and development. Market participants can briefly study the report before investing in the market and expect higher returns. According to the report, the market scenario continues to fluctuate based on many factors.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=30532

Key Players Mentioned in the Chronic Obstructive Pulmonary Disease Market Research Report:

AstraZeneca, Astellas Pharma Inc., Abbott Laboratories, GlaxoSmithKline plc., Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Circassia Pharmaceuticals, Pfizer and Almirall.

Several industries are interested in determining what the customers really want and the Chronic Obstructive Pulmonary Disease market report helps in this regard by carrying out detailed market research. Before bringing a new product to market, every business owner wants to know the demand for the product, and this market research report is the best guide for them. It further helps in meeting business requirements by covering all the latest advances in the market. The Chronic Obstructive Pulmonary Disease Market report is the best way to keep a close eye on the activities of leading competitors as well as their strategies for expanding their business. It further conducts in-depth analysis for the 2022-2028 assessment period to provide more business opportunities for business owners.

Chronic Obstructive Pulmonary Disease Market Segmentation:

Chronic Obstructive Pulmonary Disease Market, By Type

• Chronic bronchitis
• Emphysema

Chronic Obstructive Pulmonary Disease Market, By Treatment Type

• Oxygen therapy
• Lung transplant
Drug therapy
• Operation
• Others

Chronic Obstructive Pulmonary Disease Market, By End User

• Hospitals and Clinics
• Home care settings
• Others

Inquire for a discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=30532

Scope of Chronic Obstructive Pulmonary Disease Market Report

UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Answers to key questions in the report:

1. Who are the top five players in the Chronic Obstructive Pulmonary Disease market?

2. How will the Chronic Obstructive Pulmonary Disease market develop over the next five years?

3. Which product and application will occupy the lion’s share of the Chronic Obstructive Pulmonary Disease market?

4. What are the drivers and restraints of the Chronic Obstructive Pulmonary Disease Market?

5. Which regional market will show the strongest growth?

6. What will be the CAGR and size of the Chronic Obstructive Pulmonary Disease market throughout the forecast period?

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/chronic-obstructive-pulmonary-disease-market/

Visualize the Chronic Obstructive Pulmonary Disease Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and results with an integrated presentation function that saves you more than 70% of your time and resources for presentations to investors, sales and marketing, R&D and product development. products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the chronic obstructive pulmonary disease market using VMI@ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. technical data and advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768

E-mail: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Nearly a Quarter of US Investors Have Used Loans to Buy Crypto https://www.tenil.net/nearly-a-quarter-of-us-investors-have-used-loans-to-buy-crypto/ Mon, 04 Jul 2022 17:08:19 +0000 https://www.tenil.net/nearly-a-quarter-of-us-investors-have-used-loans-to-buy-crypto/

A large number of retail investors in the United States took out loans, often at exorbitant interest rates, to buy cryptocurrencies, and more than half of those investors ended up losing money, according to a recent investigation by DebtHammer.

DebtHammer surveyed over 1,500 people in the United States to learn about their crypto investing habits and how they affect the already indebted nation.

Loans for Crypto Investments

Over 21% of crypto investors said they used a loan to pay for their crypto investments, according to the survey.

Personal loans seem to be the most popular choice among investors, as more than 15% said they used one to fund their crypto purchases. Many have also used payday loans, title loans, mortgage refinances, home equity loans, and even leftover student loan funds to acquire crypto.

crypto investors loan
Chart showing the percentage of investors who used loans to invest in cryptocurrencies (Source: DebtHammer)

About 1 in 10 investors who have used a payday loan have used it to purchase cryptocurrencies. Most borrowed between $500 and $1,000 to invest in crypto, the survey showed. However, DebtHammer researchers noted that these were risky purchases despite the low amount borrowed, as payday loans averaged around 400% APR.

Retail investors who have used loans to purchase crypto have said their purchases have not always been successful. Nearly 19% of respondents said they had trouble paying at least one bill due to their crypto investments, while around 15% said they were worried about eviction, foreclosure or a car repossession. Payday loan users appeared to have suffered slightly less, with only 12% saying they had trouble paying a bill or worried about evictions, foreclosures or foreclosures.

crypto investors loan
Chart showing the percentage of crypto investors at risk of seizure, eviction, or vehicle repossession due to loans used to purchase cryptocurrencies (Source: DebtHammer)

Loans aren’t the only way investors used to buy cryptocurrencies when they ran out of money.

According to the survey, over 35% of respondents said they used a credit card to purchase crypto. While about 20% of them paid it off when the bill was due, 14% said they were paying it back gradually with an introductory offer at 0% APR or full interest.

All the borrowed money went to a handful of cryptocurrencies. The survey showed that more than half (54%) of respondents used borrowed money to buy Bitcoin (BTC). Dogecoin (DOGE) came in second, with nearly 35% of respondents saying they bought the token with loans, while just under 30% said they bought Ethereum (ETH).

crypto investors loan
Chart showing which cryptocurrencies retail investors bought with borrowed money (Source: DebtHammer)

Just under 23% of those who borrowed money to buy cryptocurrency said they did so because crypto prices had fallen sharply. About 15% said they consider cryptocurrencies a good long-term investment, while 17% said crypto prices are “historically low.”

A notable percentage of respondents (18.5%) said they borrowed money to buy cryptocurrencies because their credit card company or bank offered them a promotional interest rate of 0%.

However, not everyone who plays wins.

Of those who borrowed money to invest in cryptocurrencies, around 60% lost money. And while more than a third of them lost $1,000 or less, 6% said they lost between $50,000 and $100,000 and 5.5% said they lost more than $100,000.

Investing in cryptocurrencies with borrowed money also does not result in significant gains. The majority, 27%, earned up to $1,000, while only 7.5% earned between $1,000 and $5,000.

crypto investors loan
Chart showing how much money investors have lost or gained investing in cryptocurrencies (Source: DebtHammer)
Ruby Wax credits new treatment for lifting her out of depression https://www.tenil.net/ruby-wax-credits-new-treatment-for-lifting-her-out-of-depression/ Mon, 04 Jul 2022 16:00:00 +0000 https://www.tenil.net/ruby-wax-credits-new-treatment-for-lifting-her-out-of-depression/
Ruby Wax credits new <a class=treatment for lifting her out of depression [Instagram] Credit: Bang Showbiz” src=”https://s.yimg.com/ny/api/res/1.2/oqKhmVVxxCY9eDbL2fnN6g–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MA–/https://s.yimg.com/uu/api/res/1.2/N6_EFnjwsS0Wi9EJdDKvkg–~B/aD0wO3c9MDthcHBpZD15dGFjaHlvbg–/https://media.zenfs.com/en/bang_showbiz_628/9ec536684621755e18e648176985ca94″/>

Ruby Wax credits new treatment for lifting her out of depression [Instagram] Credit: Bang Showbiz

Ruby Wax has credited a new treatment with helping her recover from a recent bout of depression.

The 69-year-old actress revealed just two weeks ago that she was suffering from her first bout of depression in 12 years, but now believes undergoing repetitive transcranial magnetic stimulation treatment helped her.

She shared a photo of herself on Instagram, wearing a special helmet for the procedure and wrote, “I’m better now, but the quicksand extraction of depression is so slow it’s faster to see your hair grow.

“The last time it happened to me about twelve years ago it took me months to get back to what I was, this time it only took weeks.”

After joking that the procedure saved her from being one of the “walking dead,” Ruby went into detail about what it entails.

She wrote: “I’m better now but the quicksand extraction of depression is so slow it’s faster to see your hair grow. Last time this happened to me was about twelve years ago years, it took months to get back to who I used to be, this time it only took weeks.

“Here’s how I retired from being among the walking dead, there’s a new machine called rTMS (repetitive transcranial magnetic stimulation).

“If you had told me five years ago that something like this existed, I would have thought you had watched too much science fiction. rTMS is different from ECT (for electroconvulsive therapy), which is the latest saloon treatment for those who don’t.With ECT they knock you out, put some between your teeth so you don’t bite your tongue and let the tension tear.

“The electrical currents cause a little seizure that hopefully changes brain chemistry. In other words, you’re fried and even worse, there’s a good chance there’s short-term memory loss. term. Not good for any human being who wants to remember his Name.”

Ruby explained that the procedure is 60% successful and revealed how lucky she feels to be part of that percentage.

She said: “The Repetitive Transcranial Magnetic Stimulator doesn’t use electricity, it uses a magnetic pulse that kicks your neurons into action, like restarting a broken down car. It works on 60% of patients with depression. , OCD and a few other mental disorders and thank you Jesus I was in that 60 percent.

“They put something that looks like a 50s hair dryer on your head and then the banging started.

“Looks like Woody Woodpecker was dropped on the left side of your head and he’s having a hay day. Those magnets hit you about 36 times every few seconds, up to 55 times. That’s about 1,980 strokes to recalibrate your brain (not pleasant).

“I’ve had twenty sessions and a rework of meds and who would have dreamed it, I’m almost human again. I can almost smile, which is an impossibility during the dark nights of mental knives. There’s only There are a handful of places in the UK that offer treatment using this equipment, as mental illness is probably the lowest on the list when it comes to taking illness seriously.

“For me, that’s actually the most serious because a diseased brain is usually the underlying cause of most physical illnesses.

“But we know the stigma blah blah blah… and we don’t do enough of it.

“That’s why with mental illness, forget getting the right help, forget getting the right meds, forget a bed in a hospital, forget seeing a psychiatrist – so really why would they bother putting this magical equipment available to lean 1 of 4?

“I will continue to lead the fight.”

Best Kids Tablet – NBC4 WCMH-TV https://www.tenil.net/best-kids-tablet-nbc4-wcmh-tv/ Mon, 04 Jul 2022 10:18:41 +0000 https://www.tenil.net/best-kids-tablet-nbc4-wcmh-tv/

Which tablet is best for kids?

Most kids’ tablets are designed to provide entertainment, learning platforms, or both. Look for the entertainment/learning ratio you want your child to have. Tablets designed for kids usually include parental controls so that adults can set boundaries and boundaries to protect their children from exposure to unwanted images, sounds, and subjects.

Young children are happy with tablets that are essentially toys, while older children want tablets that are more like computers. If you want your child to have over 10,000 hours of kid-friendly activities to choose from, the Samsung Galaxy Tab Kids Edition, an Android-based Wi-Fi tablet, is a great choice.

What to know before buying a children’s tablet


First, decide if you want a tablet that connects to the internet or one that doesn’t. Those who don’t log in are limited to embedded content. Some tablets allow you to download and later use online content without having to maintain a permanent connection. Cheaper kids’ tablets can access the web, but have no way to download from it. Tablets that do not provide online access are seen more as toys than tablets.


Entertainment-focused tablets provide access to many different choices and levels of music, videos, and games. Most music requires monthly subscriptions to paid services. Children’s tablets typically have small screens with low resolution levels, and viewers prefer larger screens with sharper images. Players can instead have gaming-only devices.


Kids’ tablets that run standard tablet apps will cost more than those that come with lite suites of pre-chosen apps. Social media apps will appear on tablets designed for older children.

What to Look for in a Quality Kids Tablet

Parental control

Parental controls are the main reason to buy a tablet specially designed for children. Look closely at children’s tablets to see which parental controls will give you the type and level of control you want.

  • Set access limits: Parents determine what children can access and what they cannot. Parents choose whether children can go online, what they can do there and which sites to block.
  • Set content limits: Parents use tablets with this feature to limit their children to watch and stream videos and music with certain content ratings. This allows parents to block access to offensive and obscene material.
  • Set deadlines: Most kids’ tablets allow parents to set limits for the total screen time allowed per day. The best ones allow setting time limits at a more granular level, like allowing set time limits for videos, music, books, and learning or allowing access only at certain times of the day.
  • Allow or deny access to the camera: If you want to turn off the camera, look for a kids tablet that has this feature.
  • Set purchase access: Kids’ tablets with this feature allow parents to set in-app purchase levels as low as they want, all the way down to zero.


The younger the child uses a kids tablet, the more you’ll want a device that can take a beating without breaking. Rugged rubberized bumpers all around protect against drops and shatterproof glass is a must.

How much you can expect to spend on a kids tablet

The less a child’s tablet looks and acts like a regular tablet, the cheaper it will be. Small-screen tablets that play some games and run some educational apps cost $75 or less. The most popular children’s tablets cost between $100 and $200 and are aimed at a pre-teen target. These still look like a toy because they’re still built to withstand abuse, but they do almost everything a regular tablet would. Above $200, there is little difference between a children’s tablet and an adult tablet.

Kids Tablet FAQs

What about passwords and PINs?

A. You should look for tablets that can let you set and reset important login credentials through their own smartphones or computers.

Apart from parental controls, what is a child tablet used for?

A. One idea behind kids’ tablets is that kids are likely to start using expensive electronic devices long before they’ve learned the importance of handling them carefully and gently. The other is that children who are just starting to use tablets need little or nothing that a full-fledged tablet can do.

What is the best kids tablet to buy?

Best tablet for kids

Samsung Galaxy Tab Kids Edition

What do you want to know: Samsung gives kids more than 10,000 hours of kid-friendly activities to choose from.

What you will love: You set time limits for your children, so they only interact with content you trust. The 8-inch screen of this Android device has a native resolution of 1280 x 800. This 1.3 pound WiFi device is built tough, so it stands up to harsh and sometimes careless use by children, and the lithium-ion battery is included.

What you should consider: The camera is not very impressive.

Or buy: Sold by Amazon.

Best kids tablet for the price

Amazon Fire 8 tablet for kids

Amazon Fire 8 tablet for kids

What do you want to know: Amazon’s latest kid-friendly tablet comes with a massive entertainment library of thousands of videos, music, and games.

What you will love: An 8-inch HD screen and 32GB of memory are wrapped in this childproof case with a parent dashboard. It comes with a free year of AmazonKids+ which gives your kids access to over 20,000 apps, games, books, videos and educational content from PBS Kids, Disney, Nickelodeon and more. The 12-hour battery life is great for a kids’ tablet, and a USB-C cable and 5W power adapter are included. The 2-year worry-free replacement warranty makes this a great deal.

What you should consider: Some wish the screen was brighter.

Or buy: Sold by Amazon.

Worth checking out

LeapFrog Epic Academy Edition

LeapFrog Epic Academy Edition

What do you want to know: This WiFi kids tablet is the best for making learning fun outside of school.

What you will love: Parental controls allow adults to set limits and limitations for children’s online activities with the LeapSearch browser. The 7-inch multi-touch LCD screen is shatterproof and surrounded by a sturdy frame. The learning apps on this Android device with 16 GB of memory allow children to develop their reading, math and science skills. This tablet comes with a rechargeable lithium-ion battery and a free trial of LeapFrog Academy’s interactive learning programs.

What you should consider: The 7-hour battery life isn’t enough for some.

Or buy: Sold by Amazon

Do you want to buy the best products at the best prices? Check out the daily deals from BestReviews.

Sign up here to receive the weekly BestReviews newsletter for helpful tips on new products and great deals.

David Allan Van written for BestReviews. BestReviews has helped millions of consumers simplify their buying decisions, saving them time and money.

Copyright 2022 BestReviews, a Nexstar company. All rights reserved.

Incentive scheme linked to research in work for the pharmaceutical industry https://www.tenil.net/incentive-scheme-linked-to-research-in-work-for-the-pharmaceutical-industry/ Sun, 03 Jul 2022 07:58:00 +0000 https://www.tenil.net/incentive-scheme-linked-to-research-in-work-for-the-pharmaceutical-industry/

The details of the RLI scheme are not yet specified, but to be eligible for the incentives, companies may be asked to invest at least 15% of their turnover in R&D.

pharmaceutical companies | biocon | Coronavirus vaccine

Sohini Das |

The Center may announce a Research Linked Incentive (RLI) program for the pharmaceutical industry to increase contribution to research and development (R&D) and move up the innovation value chain, it said. sources close to the development.



What do you get on Business Standard Premium?


Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

First published: Sun 03 Jul 2022. 13:28 IST

AI is the secret to companies reducing carbon emissions and costs at the same time https://www.tenil.net/ai-is-the-secret-to-companies-reducing-carbon-emissions-and-costs-at-the-same-time/ Sun, 03 Jul 2022 06:04:41 +0000 https://www.tenil.net/ai-is-the-secret-to-companies-reducing-carbon-emissions-and-costs-at-the-same-time/

Philip Ashton is CEO and co-founder of 7bridges, an AI-powered logistics platform that helps businesses be more sustainable. Here he explains how companies can balance sustainability with business goals using the “Green Report”, and how the supply chain is a major contributor to our carbon footprint.

Pressure from climate-conscious consumers and net-zero deadlines set by regulators have created an urgent need to make supply chains much more sustainable. But most companies still have a long way to go when it comes to reducing carbon emissions and meeting their green goals.

Efforts are often hampered by the need to meet business goals and uncertainty about the true cost of “going green”. Without being able to accurately balance these seemingly competing priorities, companies understandably feel limited in adopting passive policies such as carbon offset schemes (whose impact is highly disputed) as a short-term solution, rather than tackling the problem at source.

But the stakes are high: with more than 80% of a company’s greenhouse gas emissions coming from its supply chain, business leaders and supply chain managers have a real opportunity to effect change.

The “Green Ratio” – optimization of costs and sustainability

The “Green Ratio” is a term that describes the ideal balance between happy shareholders – cost optimization – happy customers and happy regulators – while maximizing sustainability.

At 7bridges, companies use the AI ​​platform to focus on cost optimization, operational efficiency and risk reduction; leverage data to refine the decision-making process and create a resilient supply chain that enables a business to forecast demand, implement dynamic carrier switching, and intelligent dispatch and routing.

This means the business can adapt quickly to unforeseen disruptions, as well as seasonal changes in supply and demand.

To calculate the ‘Green Ratio’, we created a fictitious company.

We used our AI to run two simulated supply chain models using anonymized data from our customers in the pharmaceutical space. The first simulation aimed to determine the effects of cost optimization, and the second was optimized for sustainability. We then ran a third simulation to find out the point at which business and environmental goals could be optimized for both, equally.

When setting up the supply chain to operate at the lowest cost, we were able to see a savings of 23% off the reference price, with no effect on carbon emissions. When optimized solely for sustainability, it was possible to immediately reduce carbon emissions by 23% in the simulated supply chain, but with a 4% increase in baseline costs.

So you might have to pay a little more, but it’s worth it for the carbon savings.

If the company worked with suppliers who deployed a “green” fleet of electric vehicles (which would take longer), it would reduce carbon emissions by 51% in total.

The third simulation demonstrated that it is possible to optimize for both factors. Our simulation showed that the company can reduce costs by 19% and carbon emissions by 19%. During this third simulation, we also determined that the “Green Ratio” for the fictitious pharmaceutical activity was 129 kgCO2e: £1,000 (€1,178).

This means that for every thousand pounds the company spends, its carbon emissions should be limited to 129 kilograms of carbon dioxide equivalent. This number is an ideal starting point for any business looking to strike a balance between sustainability and profitability.

While running the simulations, 7bridges AI considered the data and the influence of several factors that can impact the overall carbon footprint of a supply chain. He identified the place of execution – which houses the inventory – as the most powerful lever for reducing carbon emissions.

Choosing the right execution venue has the potential to reduce a company’s carbon footprint by up to 30%, and it also has a huge influence on other factors, the most obvious being that stocking the right products or services closer to the end user means less distance traveled for delivery vehicles.

That’s far more important than more obvious “fixes,” like simply choosing a carrier with the greenest fleet, which only has a 7% impact on overall emissions.

What can companies do now?

AI technology has a crucial role to play in helping supply chain managers deal with the complexity of supply chains. It provides granularity that helps companies identify the most powerful levers when it comes to reducing their carbon footprint.

Typically, business leaders have been forced to make a choice between making short-term changes that have less impact (e.g. carbon offsetting) or longer-term adjustments (like investing in transportation greener) which are more effective but do not have an immediate effect. advantages. But now there is a third technology-based option to fix the problem immediately, while achieving long-term results.

AI can help organizations leverage the power of historical and real-time data to make optimal decisions throughout their operations.

The rising cost of carbon and why we need to act now

As emissions monitoring technology improves and climate regulations tighten, it is likely that the cost of carbon emissions will continue to rise, which will become a significant problem for businesses and individuals who rely heavily on fossil fuels.

Since 2018, the costs of carbon emissions have almost quadrupled, reaching an all-time high of nearly £84 (€98) per tonne of CO2e in 2022.

If business leaders continue to take a passive stance on sustainability in their supply chains, it’s not just their green credentials that will suffer, it’s also their bottom line. It’s time to act.

Patients Praise the Value and Benefits of Light Therapy Treatments | News, Sports, Jobs https://www.tenil.net/patients-praise-the-value-and-benefits-of-light-therapy-treatments-news-sports-jobs/ Sat, 02 Jul 2022 22:35:34 +0000 https://www.tenil.net/patients-praise-the-value-and-benefits-of-light-therapy-treatments-news-sports-jobs/

Photo provided

A ReGen pod, used at the wellness center, is shown in this undated photo.

SOUTH OGDEN — Jeff Guthrie was sick, weak, tired and depressed. After being infected with COVID-19, his symptoms persisted. The Eden resident couldn’t even walk 20 feet without having to sit up and catch his breath.

“It’s awful,” Guthrie said. “It left me with lung issues and really bad depression. That’s when Laura called me and told me to come and try a therapy session. I can’t believe how great a difference in my life.

The machine, called ReGen Pod, uses red light and near-infrared laser light therapy to improve overall health, according to the manufacturer’s website.

Laura Warburton is the owner of the Wellness Center, which has a location in Huntsville and a recently opened one in South Ogden. She said the therapy worked so well for her that she wanted to share it with others.

The therapy uses low level wavelengths of red light, which can have a biochemical effect on cells in the body and, in turn, help reduce inflammation and pain in the body. The website says the therapy can even have positive results with anxiety and depression.

“My depression is like night and day,” Guthrie said. “I have more energy. All I can say is that I lay in there for 20 minutes and I feel better.

Warburton’s journey to the wellness center began when she was diagnosed with terminal hydrocephalus, a condition in which fluid builds up in the deep cavities of the brain. The condition was the result of an accident she suffered years ago.

“The main symptoms are dementia, incontinence, uneven walking and extreme fatigue,” she said. “Over the past five years, I’ve learned to accept it and do my best. I had two brain surgeries. I was placed on a shunt which resolved most of my symptoms but still left me feeling tired and foggy most of the time.

Warburton did everything she could think of – she even moved to Mexico for a while to be closer to sea level, but the lack of her family brought her back to Utah.

“Around the same time, an ad on Facebook caught my eye. It was for a concussion support center,” she said. “I wanted to learn more to help others, not necessarily myself.”

Warburton, a resident of Huntsville, said she learned more about the full body modules and did a free session.

“I was blown away,” she said. “I’ve had so much energy – enough to quit the La-Z-Boy and start two businesses. My brain is so much better. I’m also calmer. My arthritis is gone.

According to the Cleveland Clinic, red light therapy continues to grow and shows promise in several areas of medicine, including the treatment of acne, scars, skin cancer and other medical conditions. However, the clinic states that full effectiveness for certain conditions has yet to be determined, and to date, there is no scientific evidence to support weight loss or cellulite removal.

Warburton opened her first business in her home and business boomed, she said. That’s when she decided to open her second location in South Ogden in June.

“We don’t claim to cure anything, and we don’t diagnose,” she said. “Without a doubt, the clove reduces inflammation. Inflammation causes pain. There are other full body pods available, none in Weber County. However, there is only one pod which is programmable and sends frequencies into the body. The ReGen Q8 module. Simply put, everything is energy and when measured it is called frequency.

Warburton added that the process, when pulsing frequencies through the four beneficial light spectra, is similar to acupuncture with light.

“It literally reaches every cell in your body, stimulating them to their highest and best use,” Warburton says.

Jason Smith, a chiropractor with a master’s degree in clinical neuroscience who practices at Bountiful, said he’s been using laser light therapy for more than 15 years. He said light therapy helps speed up cell division so people recover faster.

“There are thousands of research papers on the subject,” he said. “Light therapy can help with everything from post-surgery recovery, wound healing, concussions, and acne. It’s been shown to improve brain function and reduce pain. I’ve used it myself myself and I feel more energetic and creative. It feels like a magic bullet, but it improves the functioning of the body.

The only contradiction to using the capsule, Warburton said, is for people undergoing immunosuppressive therapy for cancer or other illnesses.

“The pods boost your immune system, so we never allow anyone with cancer without written approval from a doctor,” she said. “There are interesting studies for every possible disease on the Google Scholar site. Just search for ‘photobiomodulation’ and insert the disease and a number of peer-reviewed studies are available to read.”

Webmd.com also states that, although more studies are needed, red light therapy may help with dental pain, hair loss, dementia, osteoarthritis, and tendonitis.

The pod looks like a tanning bed. Once inside, the machine is programmed to deliver a pulse of light at varying levels, depending on the reason for its use. The maximum time for each session is 15 to 20 minutes. The first session is always free. After that, a discounted six-session package would cost $275. A walk-in session costs $65.

Clinton’s Janice Hill used the capsule to relieve knee pain, headaches, and anxiety.

“I didn’t feel any pain when I got out of the basket the first time. I had relief for a while,” she said. “I’ve been back to it several times and when I’m done the pain is usually gone. It’s very relaxing and definitely has other benefits. I feel more energy and more clarity in my thinking.

Guthrie said he was so pleased with the results that he sent dozens of people to try it out for themselves.

“People asked me if it was snake oil,” he said. “Well, if it’s snake oil, it worked for me.”

The wellness center is located at 1724 Combe Road in South Ogden and also at Warburton’s home in Huntsville. For an appointment, people can call 801-800-2484.


Join thousands of people who already receive our daily newsletter.

Tesla Q2 sales tumble amid supply chain, pandemic concerns https://www.tenil.net/tesla-q2-sales-tumble-amid-supply-chain-pandemic-concerns/ Sat, 02 Jul 2022 17:59:47 +0000 https://www.tenil.net/tesla-q2-sales-tumble-amid-supply-chain-pandemic-concerns/

DETROIT (AP) — Tesla’s April-June sales fell to their lowest quarterly level since last fall as supply chain issues and pandemic restrictions in China hampered production of its electric vehicles. .

The company revealed on Saturday that it sold more than 254,000 cars and SUVs from April to June, down 18% from the first three months of this year and also well below the pace of the last quarter of the year. ‘last year.

The last time Tesla sold fewer vehicles globally was in the third quarter of 2021, when it delivered 241,000.

On Friday, the rest of the industry reported a 21% drop in second-quarter sales as the average price of vehicles soared to a record $45,844 amid runaway inflation, according to JD. Power.

Tesla’s sales slump could be a harbinger of weaker second-quarter profit for the Austin, Texas-based company, which is the world’s top seller of battery-powered vehicles and has been posting net profits for nearly of three years. Tesla plans to release full results for the April-June period on July 20.

Like many other stocks, Tesla shares have been hit hard this year. But the 35% drop in Tesla’s share price wasn’t entirely related to the company’s rocky fortunes.

Tesla CEO Elon Musk also made a $44 billion bid for Twitter, which he put on hold after complaining that there were too many non-human spambot users. Much of Tesla’s value erosion has occurred since Musk became Twitter’s largest shareholder and then launched a takeover bid that raised concerns he has too much on his already crowded plate. .

Musk took to his own Twitter account, which now has more than 100 million followers, to discuss the pandemic restrictions that forced the Shanghai factory to temporarily close during the quarter. Wedbush analyst Dan Ives estimates that more than 40% of Tesla’s sales come from China and that the Shanghai plant has produced around 70,000 fewer vehicles due to the closures.

But Tesla signaled things were looking up on Saturday, saying it produced more vehicles in June than in any other month in its history. The company did not disclose the number of vehicles manufactured in June.

As of early Saturday afternoon, Musk had not tweeted about Tesla’s second-quarter sales. But he caused a stir on Friday night by ending an unusual nine-day silence on Twitter. His Friday tweets included one with him and four of his children meeting Pope Francis.

Tesla’s latest delivery numbers came out a week after an interview with Musk was published in which he described new factories in Austin and Berlin as “silver furnaces” that were losing billions of dollars because Supply chain outages were limiting the number of cars they could produce. .

In a May 30 interview with a Tesla Owners Club that was just published last week, Musk said the commissioning of the Berlin and Austin factories “is a big part of our concerns. Everything else is a very small thing,” Musk said, but added that “everything is going to be sorted out very quickly.”

Musk also discussed the return of salaried workers to offices and a possible 10% reduction in Tesla’s workforce due to a possible recession.

Supply chain outages since the start of COVID-19 two years ago have been particularly debilitating for automakers, which source parts from all corners of the globe. The lack of computer chips needed to run car computers has compounded problems for automakers and sent new and used car prices skyrocketing.

As the pandemic broke out in the United States in 2020, automakers had to shut down factories for eight weeks to help prevent the virus from spreading. Some parts companies have canceled semiconductor orders. At the same time, demand for laptops, tablets and game consoles has skyrocketed as people stuck at home upgrade their devices.

By the time automotive production resumed, chipmakers had shifted production to consumer goods, creating a shortage of weatherproof automotive-grade chips. Although Tesla has done better than other automakers, the industry still can’t get enough chips.


AP Business Writer Michael Liedtke contributed to this story from Berkeley, Calif.

Growth Hormone Type 1 Secretagogue Receptor Market 2022 by Key Players: Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd – Indian Defense News https://www.tenil.net/growth-hormone-type-1-secretagogue-receptor-market-2022-by-key-players-aeterna-zentaris-inc-alize-pharma-sas-allergan-plc-astrazeneca-plc-daiichi-sankyo-co-ltd-oxeia-biopharmaceuticals-inc-pfiz/ Sat, 02 Jul 2022 04:28:21 +0000 https://www.tenil.net/growth-hormone-type-1-secretagogue-receptor-market-2022-by-key-players-aeterna-zentaris-inc-alize-pharma-sas-allergan-plc-astrazeneca-plc-daiichi-sankyo-co-ltd-oxeia-biopharmaceuticals-inc-pfiz/

The Latest published a market study on Growth hormone secretagogue receptor type 1 Market provides an overview of current market dynamics in the Growth Hormone Secretagogue Type 1 Receptor space, as well as what our survey respondents – all outsourcing decision makers – predict the market will look like in 2028. The study divides the market in terms of revenue and volume (if applicable) and price history to estimate size and trend analysis and identify gaps and opportunities. Some of the actors covered by the study are Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd

Prepare to identify the pros and cons of the regulatory framework, local reforms and its impact on the industry. Find out how growth hormone secretagogue receptor type 1 leaders are staying ahead with our latest survey analysis

Click for Growth Hormone Secretagogue Type 1 Receptor Market Research Sample Copy Here @ https://www.maccuracyreports.com/report-sample/459771

Main highlights of the study as well as the most frequently asked questions:

1) What is so unique about this growth hormone secretagogue receptor type 1 evaluation?

Market Factor Analysis: In this economic downturn, the impact on various industries is enormous. Moreover, the increase in the gap between demand and supply resulting from the slow supply chain and production chain has made the market interesting to observe. It also discusses technological, regulatory and economic trends affecting the market. It also explains the key drivers and regional dynamics of the global market and current trends within the industry.

Market concentration: Includes C4 Index, HHI, Growth Hormone Secretagogue Type 1 Receptor Market Share (Annual) Benchmarking, Major Companies, Emerging Players with Heatmap Analysis

Market entropy: The randomness of the market highlights the aggressive steps players are taking to overcome the current scenario. Developmental activities and milestones such as expansions, technological advancements, mergers and acquisitions, joint ventures, launches are highlighted here.

Patent Analysis: Comparison of patents issued by each player per year.

Peer review: An assessment of players by financial metrics such as EBITDA, net profit, gross margin, total revenue, segmented market share, assets, etc. to understand the management efficiency, functioning and state of liquidity.

2) Why are only a few companies featured in the report?
Industry standards such as NAICS, ICB, etc. are considered the most important manufacturers. The focus is more on SMEs that are emerging and evolving in the market with their product presence and improved technology modes, the current version includes players such as Aeterna Zentaris Inc, Alize Pharma SAS, Allergan Plc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Oxeia Biopharmaceuticals Inc, Pfizer Inc, RaQualia Pharma Inc, Zeria Pharmaceutical Co Ltd etc and many more.

**Companies reported may vary due to rebranding/merger etc.

Access full report description, table of contents, table of figures, chart, etc. : https://www.maccuracyreports.com/report-sample/459771

3) What details will the competitive landscape provide?
A value proposition chapter to assess the growth hormone secretagogue type 1 receptor market. 2 page profiles of all listed companies with 3-5 year financials to track and compare overview of company, product specifications, etc.

4) What did all the regional segmentations cover? Can a specific country of interest be added?
The countries included in the analysis are North America, United States, Canada, Mexico, Europe, Germany, France, United Kingdom, Italy, Russia, countries Nordics, Benelux, Rest of Europe, Asia, China, Japan, South Korea, Southeast Asia, India, Rest of Asia, South America, Brazil, Argentina , Rest of South America, Middle East and Africa, Turkey, Israel, Saudi Arabia, United Arab Emirates and Rest of Middle East and Africa
** Countries of primary interest can be added if missing.

5) Is it possible to limit/adapt the scope of the study to the applications we are interested in?
Yes, the general version of the study is broad, but if you have a limited application in your scope and target, the study can also be customized just for those applications. It now covers Aeronautics, Airports & Other applications.

** Depending on the requirement, delivery time may vary.

To primarily understand the growth hormone type 1 secretagogue receptor market dynamics globally, the global growth hormone type 1 secretagogue receptor market is analyzed across major regions of the world. Custom study by specific region or country can be provided, usually customer prefer below

  • North America: United States of America (USA), Canada and Mexico.
    • South and Central America: Argentina, Chile, Colombia and Brazil.
    • Middle East and Africa: Kingdom of Saudi Arabia, United Arab Emirates, Turkey, Israel, Egypt and South Africa.
    • Europe: United Kingdom, France, Italy, Germany, Spain, NORDIC countries, BALTIC countries, Russia, Austria and rest of Europe.
    • Asia: India, China, Japan, South Korea, Taiwan, Southeast Asia (Singapore, Thailand, Malaysia, Indonesia, Philippines and Vietnam, etc.) and rest
    • Oceania: Australia and New Zealand

Basic segmentation details
Types of growth hormone secretagogue receptor type 1 products in depth: AZP-531, EXT-400, HM-01, OXE-103, Others.

Growth Hormone Secretagogue Receptor Type 1 Main Applications/End Users: Radiation toxicity, effects of chemotherapy, alcohol dependence, others

Geographical analysis: North America, USA, Canada, Mexico, Europe, Germany, France, UK, Italy, Russia, Nordics, Benelux, Rest of Europe, Asia, China, Japan, South Korea, South Asia – East, India, Rest of Asia, South America, Brazil, Argentina, Rest of South America, Middle East and Africa, Turkey, Israel, Saudi Arabia, United Arab Emirates and Rest of Middle East and Africa and rest of the world

For an in-depth analysis of the Growth Hormone Secretagogue Type 1 Receptor market size, a competitive analysis is provided which includes Revenue (M USD) by Players (2022-2028) and Share of market (%) by players (2022-2028) supplemented by concentration rate.

Purchase Complete 2022 Report of Growth Hormone Secretagogue Type 1 Receptor at Revised Offered Price @ https://www.maccuracyreports.com/checkout/459771

Actual figures and in-depth analysis of Growth Hormone Receptor Type 1 Secretagogue market size estimation and trends available in full report version.

Thank you for reading this article, you can also shop by section or opt for a regional report limiting the scope to North America, ANZ, Europe or MENA countries, Eastern Europe. is or the European Union.

Pharmaceutical patents under fire from the federal circuit, according to the petitions https://www.tenil.net/pharmaceutical-patents-under-fire-from-the-federal-circuit-according-to-the-petitions/ Fri, 01 Jul 2022 10:06:48 +0000 https://www.tenil.net/pharmaceutical-patents-under-fire-from-the-federal-circuit-according-to-the-petitions/

Growing frustration among pharmaceutical patentees over the Federal Circuit’s tightening of patent law provisions that require inventors to describe in detail what they have created has led to multiple Supreme Court petitions seeking to put the country’s leading patent appeals court.

Over the past decade, the United States Court of Appeals for the Federal Circuit has adopted higher standards to meet the requirements of the law that patents provide a clear written description and enable others to understand the invention. Three separate petitions for review are now asking the High Court to look at tests that have evolved from statutory language that set benchmarks for how patent holders fully disclose their inventions – the tests say lawyers have created a particularly heavy burden on the life sciences industry.

Recent decisions invalidating pharmaceutical patents held by Bristol-Myers Squibb Co. Juno Therapeutic, Biogen International GmbHand Amgen Inc. show how difficult it is for drugmakers and biotech companies to meet federal circuit standards, the attorneys said.

“I hope the Supreme Court can make a correction to the course we are currently on,” said Hailey Bureau, patent attorney at Birch, Stewart, Kolasch & Birch LLP. “The court has been going down this road for the past decade, but now it looks like the last three very recent decisions have come to a head in the last year.”

Describe an invention

Section 112(a) of the Patent Act requires that “patent claims must state what an inventor or co-inventor considers to be the invention”. From there, more specific provisions require a “written description of the invention, and of the manner and process of making and using it, in full, clear, concise and accurate terms enabling” a skilled person in the art of making and using the invention. The Federal Circuit treats this language as two separate issues, the lawyers say: a written description requirement and a clearance standard.

Both prongs of Section 112 were improperly enforced by the federal circuit, drugmakers claim, which they say led to the invalidation of patents for breakthrough cancer treatments and a blockbuster cancer drug. multiple sclerosis.

The Complete Federal Circuit held in 2010 Ariad vs. Eli Lilly ruling that the written description requirement is distinct from the authorization. Testing, however, is two sides of the same coin, Bureau said.

“They are very intertwined. If you can show clearance, you should have a written description,” Bureau said. “The court decided on its own initiative to split them into two requirements of written description and enabling, but whether or not that was Congress’s intention, it probably isn’t.”

full ownership

The Biogen and Juno Therapeutics petitions both address whether the Federal Circuit went too far in what is necessary to show that an inventor has full possession of the invention, a way of showing that there is an adequate written description.

“The question is not only how do we as claimants show possession, [but] how do we show that we have enough possession? Office said. “Based on some goalposts the Federal Circuit has set, it appears to be invisible that no one else can see except the court.”

Biogen’s patent for the drug MS Gilenya fell because the patent failed to show the invention was “effective”, prompting dissent from several judges, who said the ruling would cloud case law. Simply listing ingredients and methods once, without proving efficacy, should suffice, Judge Alan D. Lourie wrote in a dissent from the Full Federal Circuit’s decision not to rehear the case.

“If the written description standard is now going to require proof of efficacy in a patent application, it also creates a problem for pharmaceutical companies to decide when to file for patent protection,” said patent attorney Emer Simic. at Neal, Gerber & Eisenberg. LLP in Chicago. “This creates significant concern for pharmaceutical companies researching drugs for the treatment of various conditions.”

Juno’s patent failed to show how specific antibodies would work in his technique, in which T cells from a person’s own immune system are modified to attack cancer cells, the Federal Circuit ruled, reversing a jury verdict of $1.2 billion. While Juno’s patent offered some examples of antibodies, the Federal Circuit did not find it sufficient.

“It really places a very heavy burden on the plaintiff — an incredible, perhaps even untenable burden,” Bureau said. “We have found ourselves in a situation that is not ideal for patent applicants or patentees in these cases.”

Juno said the Federal Circuit went beyond the law and “erases vast swathes of patents.” Biogen warned that the decision revoking its patent would have a “chilling effect on innovation”.

Bigoen may be in the best position to win a Supreme Court grant, Simic said, pointing to the split between judges and the High Court’s denial of other petitions involving gender claims – patents that cover a group of related substances, rather than a specific compound – such as those at issue in the Juno and Amgen petitions.

“Impossible Burden”

Last year, the Federal Circuit found that Amgen’s patents on its cholesterol drug Repatha, which covered hundreds of distinct antibodies, were too broad to be valid, failing the clearance requirement .

The ruling created a new hurdle for gender claims, Amgen argued in its Supreme Court petition, saying the Federal Circuit expanded the test to require the patent to allow a qualified expert to identify and make cumulatively almost all possible variants of the invention without substantial. time and effort.

Teaching every gender assertion which works and which doesn’t would be an impossible burden, said Stanford University law professor Mark Lemley.

“This is going to make it difficult for almost everyone in the pharma and bio space to get a gender claim in the future,” Lemley said. “I don’t think the lawyers and the pharmaceutical companies who are writing the patents have somehow fully focused on the fact that, you know, when these things come to court years later, they’re not going to survive.”

If the Juno and Amgen decisions are left in place by the Supreme Court, no attempt to define an antibody will be enough to satisfy the Federal Circuit, said University of Illinois law professor Jacob S. Sherkow, who with Lemley wrote an article about antibody patents falling in court of appeal.

“Most importantly, it leaves us in a world where almost all antibody patents covering any major product, any treatment, any diagnostics – any patent covering antibodies – will all be subject to ‘be invalidated under that same standard,’ Sherkow said. said.

“It would only erase billions of dollars worth of intellectual property.”